National Health Investors (NHI) Could Be 9% Below Fair Value After Q3 Earnings

National Health Investors (NHI) just delivered third quarter 2026 results that radically reshaped its income statement, with net income climbing to US$563.53 million and earnings per share reaching US$11.47 from continuing operations.

Despite the sharp earnings headline, National Health Investors’ recent trading tells a more measured story. The 30 day share price return is 9.84%, while the year to date share price has declined 7.31% as investors weigh the earnings jump, recent asset sales and the newly affirmed US$0.94 dividend. Over longer periods, the 3 year total shareholder return of 62.03% and 5 year total shareholder return of 64.94% indicate that longer term holders have still seen solid overall gains.

Spot opportunities beyond National Health Investors by scanning a curated shortlist of income focused real estate stocks with resilient fundamentals through our 6 dividend fortresses.

The share price is up over the past month but still down for 2026, and earnings look transformed. Does that mix still tilt the risk reward in favour of new National Health Investors buyers at today’s valuation?

Most Popular Narrative: 9% Undervalued

Against a last close of $71.23, the analyst consensus Narrative on Simply Wall St places National Health Investors’ fair value at $78.50, implying roughly a 9% discount that hinges on how effectively management executes its senior housing and SHOP pivot.

The main factor that has to go right is successful reinvestment of the $560 million NHC sale proceeds and sizeable liquidity into private pay senior housing and SHOP at returns that offset higher G&A and near term FFO pressure.

The current valuation implies the market is discounting the shift toward higher SHOP exposure, the large acquisition pipeline, and secular senior housing demand in a way that leaves National Health Investors shares pricing in modest expectations relative to this narrative, which is more bullish.

See why 18 investors see National Health Investors as 9% undervalued.

Result: Fair Value of $78.50 (UNDERVALUED)

Still, the narrative can crack if weaker same store SHOP performance and rising G&A costs continue to pressure normalized FFO and stall the senior housing pivot story.

Find out about the key risks to this National Health Investors narrative.

Next Steps

Mixed messages in the recent data for National Health Investors. Act while the details are fresh by weighing both sides yourself through our 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond National Health Investors?

If you stop with National Health Investors, you risk missing other opportunities where quality, valuation and income potential line up in your favour across different sectors.

• Target stronger income potential by scanning a curated pool of reliable payers through our 6 dividend fortresses.
• Hunt for mispriced quality by filtering companies that combine solid fundamentals with market pessimism using the 33 high quality undervalued stocks.
• Stack the odds toward resilience by focusing on businesses with cleaner balance sheets through the list of solid balance sheet and fundamentals (25 results).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com